FLT3 1p19q LOHAdenovirusAPC I1307KBCR/ABL RT-PCRBK VirusBone Marrow EngraftmentBordetella pertussisChlamydiaCytomegalovirusEnterovirusEpstein-Barr VirusFLT3GonorrheaHCV QualitativeHCV QuantitativeHIV-1 RNA QuantitativeHSVIgH Gene RearrangementJC VirusMicrosatellite InstabilityPLA1/PLA2 GenotypingSpecimen Identity TestingTCR-gamma PCRVaricella-Zoster virus (VZV)

Clinical Background Clinical Utility Assay Principle Results Sample Requirements Case Tutorial References   Written by: Karin Berg, M.D. Clinical Background: AML in general has a poor prognosis. Recent studies have described mutation of the Flt3 receptor to be the most important prognostic factor in AML, with Flt3 mutants having a worse outcome and response to standard chemotherapeutic interventions. Targeted pharmacologic interventions to specifically inhibit the mutant Flt3 receptor are beginning clinical trials.

Homepage | Site Info | Contact Us | Links | Search

Pathology Homepage Copyright © 1999 - 2005 The Johns Hopkins University All rights reserved. No part of this website may be reproduced in any form or by any means or incorporated into any information retrievel system, electronic or mechanical, without the written permission of JHU.